The HEADWIND Study - Part 2

Diabetes Clinical Trial

— HEADWIND  

Official title:

Non-randomised, Controlled, Interventional Single-centre Study for the Design and Evaluation of an In-vehicle Hypoglycaemia Warning System in Diabetes - The HEADWIND Study Part 2

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04569630
• Other study ID #: HEADWIND 2
• Status: Completed
• Phase: N/A
• Start date: October 1, 2020
• Est. completion date: May 28, 2021

Study information

• Verified date: June 2021
• Source: University Hospital Inselspital, Berne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To analyse driving behavior of individuals with type 1 diabetes in eu- and progressive hypoglycaemia while driving in a real car. Based on the driving variables provided by the car the investigators aim at establishing algorithms capable of discriminating eu- and hypoglycemic driving patterns using machine learning neural networks (deep machine learning classifiers).

Description:

Hypoglycaemia is among the most relevant acute complications of diabetes mellitus. During hypoglycaemia physical, psychomotor, executive and cognitive function significantly deteriorate. These are important prerequisites for safe driving. Accordingly, hypoglycaemia has consistently been shown to be associated with an increased risk of driving accidents and is, therefore, regarded as one of the relevant factors in traffic safety. Despite important developments in the field of diabetes technology, the problem of hypoglycaemia during driving persists. Automotive technology is highly dynamic, and fully autonomous driving might, in the end, resolve the issue of hypoglycemia-induced accidents. However, autonomous driving (level 4 or 5) is likely to be broadly available only to a substantially later time point than previously thought due to increasing concerns of safety associated with this technology. Therefore, solutions bridging the upcoming period by more rapidly and directly addressing the problem of hypoglycemia-associated traffic incidents are urgently needed.

On the supposition that driving behaviour differs significantly between euglycaemic state and hypoglycaemic state, the investigators assume that different driving patterns in hypoglycemia compared to euglycemia can be used to generate hypoglycemia detection models using machine learning neural networks (deep machine learning classifiers).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: May 28, 2021
• Est. primary completion date: May 27, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 60 Years

Eligibility

Inclusion Criteria:

• Informed consent as documented by signature

• Type 1 Diabetes mellitus as defined by WHO for at least 1 year or confirmed C-peptide negative (<100pmol/l with concomitant blood glucose >4 mmol/l)

• Age between 21-60 years

• HbA1c = 9.0 %

• Functional insulin treatment with good knowledge of insulin self- management

• Passed driver's examination at least 3 years before study inclusion. Possession of a valid, definitive Swiss driver's license.

• Active driving in the last 6 months.

Exclusion Criteria:

• Contraindications to the drug used to induce hypoglycaemia (insulin aspart), known hypersensitivity or allergy to the adhesive patch used to attach the glucose sensor.

• Pregnancy or intention to become pregnant during the course of the study, lactating women or lack of safe contraception

• Other clinically significant concomitant disease states as judged by the investigator

• Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator

• Renal failure

• Hepatic dysfunction

• Coronary heart disease

• Other cardiovascular disease

• Epilepsy

• Drug or alcohol abuse

• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant

• Participation in another study with an investigational drug within the 30 days preceding and during the present study

• Total daily insulin dose >2 IU/kg/day

• Specific concomitant therapy washout requirements prior to and/or during study participation

• Current treatment with drugs known to interfere with metabolism or driving performance

Related Conditions & MeSH terms

• Diabetes
• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Hypoglycemia

Intervention

Other:
• Controlled hypoglycaemic state while driving
Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Driving data will be recorded in 4 subsequent glycemic states using an adapted hypoglycemic clamp protocol: euglycemia (d1, 5-8 mmol/l), progressive hypoglycaemia (d2, declining from 4.5 to 2.5 mmol/l), stable hypoglycemia (d3, 2.0-2.5 mmol/l), and again in euglycaemia (d4, 5-8 mmol/l). Patients will be blinded to their glucose levels.

Locations

Country	Name	City	State
Switzerland	Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism	Bern

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne	ETH Zurich, University of St.Gallen

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy of the HEADWIND-model: Diagnostic accuracy of the hypoglycemia warning system (HEADWIND) in detecting hypoglycemia (blood glucose < 3.9 and < 3.0 mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC).	Accuracy of the HEADWIND-model will be assessed using real car driving data recorded in progressive hypoglycemia and driving data will be analysed using applied machine learning technology for hypoglycemia detection.	240 minutes
Secondary	Change of swerving	Change of swerving during driving in hypoglycemia (< 3.9mmol/L) will be compared to euglycemia (5.5 mmol/L). Driving parameters will be recorded by the study car.	240 minutes
Secondary	Change of spinning	Change of spinning during driving in hypoglycemia (< 3.9mmol/L) will be compared to euglycemia (5.5 mmol/L). Driving parameters will be recorded by the study car.	240 minutes
Secondary	Change of velocity	Change of velocity during driving in hypoglycemia (< 3.9mmol/L) will be compared to euglycemia (5.5 mmol/L). Driving parameters will be recorded by the study car.	240 minutes
Secondary	Change of steer	Change of steer during driving in hypoglycemia (< 3.9mmol/L) will be compared to euglycemia (5.5 mmol/L). Driving parameters will be recorded by the study car.	240 minutes
Secondary	Change of brake	Change of brake during driving in hypoglycemia (< 3.9mmol/L) will be compared to euglycemia (5.5 mmol/L). Driving parameters will be recorded by the study car.	240 minutes
Secondary	Change of steer torque	Change of steer torque during driving in hypoglycemia (< 3.9mmol/L) will be compared to euglycemia (5.5 mmol/L). Driving parameters will be recorded by the study car.	240 minutes
Secondary	Change of steer speed	Change of steer speed during driving in hypoglycemia (< 3.9mmol/L) will be compared to euglycemia (5.5 mmol/L). Driving parameters will be recorded by the study car.	240 minutes
Secondary	Defining the glycemic level when driving performance is decreased	Plasma-glucose level (mmol/L) when driving performance begins to be impaired will be assessed based on significantly altered driving parameters in serious hypoglycemia (< 3.0 mmol/L) compared to euglycemia (5.5mmol/L).	240 minutes
Secondary	Driving performance before and after hypoglycemia based on driving parameters (swerving, spinning, velocity, steer, brake, steer torque, steer speed)	Based on significantly altered driving parameters in serious hypoglycemia (< 3.0 mmol/L) driving performance based on swerving, spinning, velocity, steer, brake, steer torque and steer speed, before and after hypoglycemia will be assessed	240 minutes
Secondary	Change of heart-rate	Change of heart-rate during driving in hypoglycemia will be compared to euglycemia. Change of heart-rate will be measured with a holter-ecg and wearable devices.	240 minutes
Secondary	Change of heart-rate variability	Change of heart-rate variability during driving in hypoglycemia will be compared to euglycemia. Heart-rate variability will be measured with a holter-ecg and wearable devices.	240 minutes
Secondary	Change of electrodermal activity (EDA)	Change of EDA during driving in hypoglycemia will be compared to euglycemia. EDA will be measured with wearable devices.	240 minutes
Secondary	Change of skin temperature	Change of skin temperature during driving in hypoglycemia will be compared to euglycemia. Change of skin temperature will be measured with wearable devices and a thermal camera.	240 minutes
Secondary	Change of eye movement	Change of eye movement and gaze behaviour during driving in hypoglycemia will be compared to euglycemia. Eye movement of the participant will be recorded by a camera and an eye-tracker.	240 minutes
Secondary	Change of facial expression	Change of facial expression during driving in hypoglycemia will be compared to euglycemia. Facial expression will be recorded by a camera.	240 minutes
Secondary	Diagnostic accuracy in detecting hypoglycemia (blood glucose <3.9 mmol/l and <3.0 mmol/l) and hyperglycemia (blood glucose >13.9 mmol/l and >16.7 mmol/l) quantified as the area under the receiver operator characteristics curve using physiological data	Accuracy of dysglycemia detection using physiological data (heart-rate, heart-rate variability, skin temperature, EDA) recorded with wearable devices during the study period will be analysed using applied machine learning technology.	Throughout the study, expected to be up to 12 months
Secondary	Diagnostic accuracy in detecting hypoglycemia (blood glucose < 3.9 mmol/l and < 3.0 mmol/l) quantified as the area under the receiver operator curve (AUC-ROC) using video data	Using video data recorded by a camera and a thermal camera accuracy in hypoglycaemia detection will be analysed with applied machine learning technology.	Throughout the study, expected to be up to 12 months
Secondary	Diagnostic accuracy in detecting hypoglycemia (blood glucose < 3.9 mmol/l and < 3.0 mmol/l) quantified as the area under the receiver operator curve (AUC-ROC) using eye-tracking data	Using eye-tracking data recorded by a camera and an eye-tracker (to record gaze behaviour) accuracy in hypoglycemia detection will be analysed with applied machine learning technology.	Throughout the study, expected to be up to 12 months
Secondary	CGM accuracy during the controlled hypoglycemic state	Accuracy (mean absolute relative difference, MARD) of CGM Sensor (Dexcom G6) in euglycemia (3.9 - 10 mmol/L), hypoglycemia (3.0 - 3.9mmol/L) and severe hypoglycemia (< 3.0 mmol/L) will be assessed based on plasma glucose measurements	240 minutes
Secondary	CGM time-delay during the controlled hypoglycemic state	Time-delay (minutes) of CGM Sensor (Dexcom G6) during progressive hypoglycemia (hypoglycemic clamp) will be assessed compared to plasma glucose.	240 minutes
Secondary	Change of glucagon	Change of glucagon before driving, during driving in euglycemia (5.5mmol/L), in hypoglycemia (< 3.9mmol/L), severe hypoglycemia (< 3mmol/L) and after hypoglycemia will be assessed.	240 minutes
Secondary	Change of growth hormone (GH)	Change of GH before driving, during driving in euglycemia (5.5mmol/L), in hypoglycemia (< 3.9mmol/L), severe hypoglycemia (< 3mmol/L) and after hypoglycemia will be assessed.	240 minutes
Secondary	Change of catecholamines	Change of catecholamines before driving, during driving in euglycemia (5.5mmol/L), in hypoglycemia (< 3.9mmol/L), severe hypoglycemia (< 3mmol/L) and after hypoglycemia will be assessed.	240 minutes
Secondary	Change of cortisol	Change of cortisol before driving, during driving in euglycemia (5.5mmol/L), in hypoglycemia (< 3.9mmol/L), severe hypoglycemia (< 3mmol/L) and after hypoglycemia will be assessed.	240 minutes
Secondary	Change of insulin	Insulin levels will be measured before driving, during driving in euglycemia (5.5mmol/L), in hypoglycemia (< 3.9mmol/L), serious hypoglycemia (< 3mmol/L) and after hypoglycemia will be assessed.	240 minutes
Secondary	Glycemic level at time point of hypoglycemia detection by the HEADWIND-model	Blood glucose at time point of hypoglycemia detection by the HEADWIND-model will be determined.	240 minutes
Secondary	Comparison CGM and HEADWIND-model regarding time-point of hypoglycemia detection	Time point of hypoglycemia detection by CGM will be compared to time point of hypoglycemia detection by the HEADWIND-model.	240 minutes
Secondary	Comparison CGM and HEADWIND-model regarding glycemia	Blood glucose at time point of hypoglycemia detection by the HEADWIND- model compared to glucose value of CGM at same time point will be assessed.	240 minutes
Secondary	Accuracy-comparison of HEADWIND-model and HEADWINDplus-model	Diagnostic accuracy of the hypoglycaemia warning system (HEADWIND) to detect hypoglycaemia (blood glucose < 3.9 mmol/l and < 3.0 mmol/l) quantified as the area under the receiver operator characteristics curve (AUC ROC) using only driving parameters (HEADWIND-model) will be compared to the HEADWIND-model with the additional integration of physiological parameters, video and eye tracker data, in particular heart-rate, heart-rate variability, electrodermal activity (EDA), skin temperature and facial expression (HEADWINDplus-model)	240 minutes
Secondary	Self-estimation of glucose and hypoglycemia	Evaluation of self-estimated glucose during progressive hypoglycemia and correlation with measured blood glucose.	240 minutes
Secondary	Self-estimation of driving performance	Evaluation of self-estimated driving-performance in severe hypoglycemia (< 3.0 mmol/L) compared to euglycemia (5.5mmol/L). Self-estimated driving performance will be assessed on a absolute 7-point scale from 0-6 (a lower value means better outcome).	240 minutes
Secondary	Time point of need-to-treat	Time point of self-perceived need-to-treat (hypoglycemia) compared to time point of hypoglycemia detection by the HEADWIND-model and CGM.	240 minutes
Secondary	Self-perception of hypoglycemia symptoms	Correlation of perceived hypoglycemia symptoms on a scale from 0-6 (0 means better outcome) to measured blood glucose.	240 minutes
Secondary	Self-perception of hypoglycemia symptoms compared to baseline hypoglycemia awareness	Correlation and comparison of perceived hypoglycemia symptoms on a scale from 0-6 (0 means better outcome) to baseline hypoglycemia awareness (Clarke-Score and Gold-Score, for both tests a score of higher or equal to 4 points indicates impaired awareness of hypoglycemia).	240 minutes
Secondary	Driving mishaps and interventions by the driving instructor in euglycaemia (5-8 mmol/l), hypoglycaemia (< 3.9 mmol/l) and severe hypoglycaemia (< 3.0 mmol/l).	Driving mishaps and interventions will be assessed by the driving instructor using an assessment questionnaire with 4 questions on a 7 point Likert scale (lower value means worse outcome)	240 minutes
Secondary	Direct comparison of driving performance scores assessed by the driving instructor in euglycemia (5-8 mmol/l), hypoglycaemia (<3.9 mmol/l) and severe hypoglycaemia (< 3.0 mmol/l)	Driving performance will be assessed by the driving instructor using an assessment questionnaire with a score from 1 to 7 (7 means the best outcome)	240 minutes
Secondary	Incidence of Adverse Events (AEs)	Adverse Events will be recorded at each study visit.	Throughout the study, expected to be up to 12 months
Secondary	Incidence of Serious Adverse Events (SAEs	Serious Adverse Events will be recorded at each study visit.	Throughout the study, expected to be up to 12 months
Secondary	Pre-test perception of technology in general	Perception of technology in general will be assessed via questionnaire based self-reports (technology readiness index) measures on the 5-point Likert Scale ranging from "strongly disagree" to "strongly agree" with a scale ranging from -2 to 2 with higher values representing a better outcome (after inversion of negative items). The total score will be averaged across participants and used individually to support the interview responses when necessary.	Throughout the study, expected to be up to 12 months
Secondary	Pre-test experience with in-vehicle voice assistants (IVAs) and technology in general	Pre-test experience with IVAs and technology in general will be assessed via questionnaire based self-reports (questionnaire of technology use and acceptance). The constructs Performance expectancy, Effort expectancy, Social influence, Facilitating conditions, Hedonic motivation, and Behavioural intention are measured on the 7-point Likert scale from "strongly disagree" to "strongly agree" with a scale range from -3 to 3 with higher values representing a better outcome. The construct Use is measured on the 7-point Likert scale ranging from "never" to "always" with a scale range from -3 to 3. The total score will be averaged per construct and across participants and used individually to support the interview responses when necessary.	Throughout the study, expected to be up to 12 months
Secondary	Direct comparison between IVA's prompts and the behavioral responses	Direct comparison of conversational turns between IVA and patient during the ecological momentary assessment and the hypoglycaemia support.	240 minutes
Secondary	Self-report of blood sugar level while driving (i.e. ecological momentary assessment)	Comparison of perceived blood sugar level to measured blood glucose, perceived blood sugar level between drives (see outcome 21), and baseline hypoglycemia awareness (Clarke-Score and Gold-Score, for both tests a score of higher or equal to 4 points indicates impaired awareness of hypoglycemia).	240 minutes
Secondary	Comparison of cognitive trust in competence and session alliance with IVA to warning type	Cognitive trust in competence with IVA will be assessed via questionnaire based self-reports (Cognitive trust in competence construct from Trust and adoption of recommendations agents questionnaire), measured on the 7-point Likert scale from "strongly disagree" to "strongly agree" with a scale range from -3 to 3 and with higher values representing a better outcome. Session alliance with IVA will be assessed via questionnaire based self-reports (item from Session Alliance Inventory), measured on the 6-point Likert scale from "not at all" to "completely" with a scale range from 0 to 5 and with higher values representing a better outcome. The questionnaire will be submitted after delivering IVA's support intervention and will be compared with the type of warning delivered (i.e. disclosure vs no disclosure).	240 minutes
Secondary	General user experience of the early hypoglycaemia warning system (EWS)	General user experience of the EWS will be assessed via questionnaire based self-reports (questionnaire for User experience questionnaire and van der Laan scale) measured on an analogue scale with adjective at its extremes (e.g. easy to learn-hard to learn, boring-exciting, good-bad, etc.) with a scale range from 0 to 100. The scores will be averaged for each scale across participants and used individually to support the interview responses when necessary.	Throughout the study, expected to be up to 12 months
Secondary	Acceptance and use of the EWS	Acceptance and use of the EWS will be assessed via questionnaire based self-reports (questionnaire of technology use and acceptance) measured on the 7-point Likert scale from "strongly disagree" to "strongly agree" with a scale range from -3 to 3 with higher values representing a better outcome. The total score will be averaged per construct and across participants and used individually to support the interview responses when necessary.	Throughout the study, expected to be up to 12 months
Secondary	Cognitive trust in competence and emotional trust in the recommendations from IVA	Cognitive trust in competence and emotional trust in the recommendations from IVA will be assessed via questionnaire based self-reports (Cognitive trust in competence and emotional trust constructs from Trust and adoption of recommendations agents questionnaire) measured on the 7-point Likert scale from "strongly disagree" to "strongly agree" with a scale range from -3 to 3 and with higher values representing a better outcome. The total score will be averaged per construct and across participants and used individually to support the interview responses when necessary	Throughout the study, expected to be up to 12 months
Secondary	Perceived working alliance with IVA	Perceived working alliance with the IVA will be assessed via questionnaire based self-reports (session alliance inventory) measured on the 6-point Likert scale from "not at all" to "completely" with a scale range from 0 to 5 and with higher values representing a better outcome. The total score will be averaged per construct and across participants and used individually to support the interview responses when necessary	Throughout the study, expected to be up to 12 months